# VSIG2 Protein, Human (HEK293, His)

| | |
|---|---|
| **Cat. No.:** | HY-P70503 |
| **Synonyms:** | V-Set and Immunoglobulin Domain-Containing Protein 2; Cortical Thymocyte-Like Protein; CT-Like Protein; VSIG2; CTH; CTXL |
| **Species:** | Human |
| **Source:** | HEK293 |
| **Accession:** | Q96IQ7 (V24-A243) |
| **Gene ID:** | 23584 |
| **Molecular Weight:** | 29-35 kDa |

## PROPERTIES

| | |
|---|---|
| **AA Sequence** | V E V K V P T E P L S T P L G K T A E L T C T Y S T S V G D S F A L E W S F V Q<br>P G K P I S E S H P I L Y F T N G H L Y P T G S K S K R V S L L Q N P P T V G V<br>A T L K L T D V H P S D T G T Y L C Q V N N P P D F Y T N G L G L I N L T V L V<br>P P S N P L C S Q S G Q T S V G G S T A L R C S S S E G A P K P V Y N W V R L G<br>T F P T P S P G S M V Q D E V S G Q L I L T N L S L T S S G T Y R C V A T N Q M<br>G S A S C E L T L S V T E P S Q G R V A |
| **Appearance** | Lyophilized powder. |
| **Formulation** | Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2. |
| **Endotoxin Level** | <1 EU/μg, determined by LAL method. |
| **Reconsititution** | It is not recommended to reconstitute to a concentration less than 100 μg/mL in $ddH_2O$. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose). |
| **Storage & Stability** | Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage. |
| **Shipping** | Room temperature in continental US; may vary elsewhere. |

## DESCRIPTION

| | |
|---|---|
| **Background** | V-set and immunoglobulin domain-containing protein 2, also known as corticothymocyte-like protein, CT-like protein and VSIG2, is a single-generation type I membrane protein. VSIG2 is highly expressed in the stomach and colon and weakly expressed in the bladder and lungs. VSIG2 is associated with immune invasion and antigen presentation of colon cancer (COAD), and it can be used as a potential biomarker or therapeutic target for COAD. VSIG2 promotes the malignant progression of pancreatic ductal adenocarcinoma through LAMtor2-mediated mTOR activation. VISG2 has been associated with a variety of diseases, in corneal samples from Fuchs patients with endothelial corneal dystrophy (FECD), in intestinal |

biopsies from patients with irritable bowel syndrome (IBS-D), in plasma from patients with acute tubule injury and interstitial fibrosis/tubular atrophy, and in plasma from patients with sudden heart failure. VSIG2 was found to be significantly upregulated[1][2][3].



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA